PPD与Pfizer Inc. 辉瑞制药签署新的服务协议

美国时间8月3日， PPD宣布已与Pfizer Inc.辉瑞制药签署了一项为期三年的新协议，PPD将继续为辉瑞制药提供药物开发服务，以推进辉瑞制药的产品组合。根据协议条款，辉瑞制药将有权额外延长协议期限两年，协议的具体财务细节未披露。

该协议建立在两家公司现有关系的基础上，PPD在全球临床开发和实验室服务方面提供广泛的专业知识，支持辉瑞制药在多个治疗领域的药物开发计划。

PPD董事长兼首席执行官David Simmons表示:“我们本着团结一致的宗旨，致力于通过创新的解决方案、高质量的执行以及我们优秀团队的奉献，帮助辉瑞制药提供令人振奋的新疗法，巩固我们与辉瑞制药的长期合作关系。PPD将一如既往地继续支持辉瑞制药,共同寻求改善患者健康的突破与创新性疗法。我们很荣幸能够共同采取下一步行动，为实现更健康的世界做出贡献。”

WILMINGTON, N.C., (August 3, 2020) – PPD, Inc. (Nasdaq:PPD), a leading global contract research organization, today announced it has signed a new three-year agreement with Pfizer Inc. to provide drug development services to advance Pfizer’s portfolio. Under the terms of the agreement, Pfizer has the right to extend the term for additional two-year periods. Financial details of the agreement were not disclosed.

The agreement builds on the companies’ existing relationship, in which PPD provides wide-ranging expertise in global clinical development and laboratory services to support Pfizer’s drug development initiatives across multiple therapeutic areas.

“United in purpose, we are committed to building on our long-standing relationship with Pfizer with innovative solutions, quality execution and the dedication of our talented teams to help Pfizer deliver exciting new therapies,” said David Simmons, PPD’s chairman and CEO. “PPD is strategically positioned to continue supporting Pfizer in its pursuit of breakthroughs that change patients’ lives. We are privileged to take the next steps together and contribute to Pfizer’s initiatives to achieve a healthier world.”

关于PPD：

PPD是一家全球领先的医药研发外包服务公司（CRO），提供全面的综合药物研发，实验室与生命周期管理服务。我们的客户及合作伙伴包括制药，生物技术，医疗器械，学术机构以及政府组织等。PPD在全球46个国家设有办事处，拥有超过24,000名专业员工。PPD借助创新的前沿技术，专业的治疗知识以及坚定的质量承诺，帮助客户及合作伙伴改善药物开发的成本-时间曲线，并优化价值，研制创新、有效和安全的医疗产品，为改善人类健康作出更大的贡献。

更多信息，请访问公司官网：www.ppd.com